SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较

doi:10.11904/j.issn.1002-3070.2017.01.005

Abstract

Abstract: Objective To investigate the clinical efficacy of SOX and XELOX in neoadjuvant chemotherapy for advanced gastric carcinoma.Methods Seventy-five cases with advanced gastric carcinoma were selected from our hospital from Feb 1,2011 to Oct 1,2015.SOX and XELOX were used to these patients treatment.The relationship between SOX and XELOX with tumor stage,clinical curative effect evaluation,operation,postoperative pathology,adverse reaction,survival analysis with advanced gastric carcinoma had been analyzed retrospectively.Results The efficacy of SOX and XELOX were 47.22%,41.03%.Compared with the two groups,the CT curative effect evaluation,effective rate,disease control rate had no significant differences(P＞0.05).The median survival time of DFS and OS were significant between the two groups(P＜0.05).Conclusion The SOX and XELOX for neoadjuvant chemotherapy of advanced gastric carcinoma treatment is safety and effective,and the XELOX is better than SOX in terms of long-term effect,prognosis and clinical benefits.

Key words: Neoadjuvant chemotherapy, Advanced gastric carcinoma, Effective rate, Disease free survival, Overall survival

CLC Number:

R735.2

CHEN Li, ZHANG Yuxin, ZUO Yanjiao, MA Fei, SONG Hongjiang, XUE Yingwei. The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 23-30.

References

1 Rebecca LS,Kimberly DM,Ahmedin J,et al.Cancer Statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
2 Strong VE,Wu AW,Selby LV,et al.Differences in gastric cancer survival between the U.S.and China[J].J Surg Oncol,2015,112(1):31-37.
3 Marrelli D,Polom K,de Manzoni G,et al.Multimodal treatment of gastric cancer in the west:where are we going?[J].World J Gastroenterol,2015,21(26):7954-7969.
4 Fontana E,Smyth EC.Novel targets in the treatment of advanced gastric cancer:a perspective review[J].Ther Adv Med Oncol,2016,8(2):113-125.
5 Tian SB,Yu JC,Kang WM,et al.Effect of neoadjuvant chemotherapy treatment on prognosis of patients with advanced gastric cancer:a retrospective study[J].Chin Med Sci J,2015,30(2):84-89.
6 Tao F,Bu ZD,Li ZY,et al.Neoadjuvant chemoradiation therapy for resectable esophago gastric adenocarcinoma:a meta-analysis of randomized clinical trials[J].BMC Cancer,2015,15:322-331.
7 Wang X,Wang ML,Zhou LY,et al.Randomized phaseⅡstudy comparing paclitaxel with S-1 vs.S-1 as first-line treatment in patients with advanced gastric cancer[J].Clin Transl Oncol,2013,15:836-842.
8 Bang YJ,Kim YW,Yang HK,et al.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label,randomised controlled trial[J].Lancet,2012,379(9813):315-321.
9 Knight G,Earle CC,Cosby R,et al.Neoadjuvant or adjuvant therapy for resectable gastric cancer:a systematic review and practice guideline for North America[J].Gastric Cancer,2013,16:28-40.
10 Ba-Ssalamah A,Prokop M,Uffnann M,et al.Dedicated multidetector CT of the stamach spectrum of diseases[J].Radio Graphics,2003,23(3):625-645.
11 Yoshikawa T,Tanabe K,Nishikawa K,et al.Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy:cohort evaluation within a randomized phase II study[J].Ann Surg Oncol,2014,21(Suppl 3):385-389.
12 Oh SY,Kwon HC,Jeong SH,et al.A phase Ⅱ study of S-1 and oxaliplatin(SOX)combination chemotherapy as a first line therapy for patients with advanced gastric cancer[J].Invest New Drugs,2012,30(1):350-356.
13 Luo HY,Xu RH,Wang F,et al.Phase Ⅱ trial of XELOX as first-line treatment for patients with advanced gastric cancer[J].Chemotherapy,2010,56(2):94-100.
14 Aoyama T,Yoshikawa T,Watanabe T,et al.Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients[J].Gastric Cancer,2012,15(1):76-82.
15 Tang L,Li ZY,Li ZW,et al.Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT:a comparison with pathological regression[J].Clinical Radiology,2015,70:1198-1204.
16 Koizumi W,Takiuchi H,Tsuburaya Y,et al.PhaseⅡstudy of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer(G-SOX study)[J].Ann Oncol,2010,21(5):1001-1005.
17 李涛,冯道夫,梁美霞,等.进展期胃癌应用SOX方案新辅助化疗对肿瘤TNM分期的影响[J].世界华人消化杂志,2014,22(2):249-252.
18 肖康,戈伟.奥沙利铂联合卡培他滨的新辅助化疗治疗进展期胃癌的疗效及安全性[J].中国肿瘤临床与康复,2016,23(3):261-263.
19 靖昌庆,李乐平,王金中.XELOX和FOLFOX4新辅助化疗方案对不能手术切除的局部进展期胃癌的疗效比较[J].中华消化外科杂志,2010,9(6):430-433.
20 张剑军,郑志超,赵岩,等.FOLFOX、XELOX、SOX 方案用于局部进展期胃腺癌的疗效及安全性比较[J].山东医药,2014,54(33):44-45.
21 Zhu YP,Sheng LL,Wang L,et al.Clinical efficacy of oxaliplatin combined with capecitabine(XELOX)and oxaliplatin combined with S-1(SOX)on advanced gastric cancer[J].Cancer Res Prev Treat,2014,41(7):815-819.
22 李远军,邢娟,吴翰昌,等.奥沙利铂联合替吉奥(SOX)与奥沙利铂联合卡培他滨(XELOX)治疗中国进展期胃癌患者的Meta 分析[J].中国生化药物杂志,2015,5(35):57-60.

[1]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[2]	LUO Jianing, HAO Chuncheng, ZHANG Jianxin, LU Jiangyue, GE Xiaofeng. Effect of postoperative adjuvant radiotherapy on prognosis of triple-negative breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 411-416.
[3]	ZHANG Xi ,CHEN Li ,XUE Yingwei. Prognostic value of CEA and CA19-9 expression in peripheral blood of patients with advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 342-347.
[4]	DAI Meng, LI Rui, LIU Guiting, LIANG Jinlong, FENG Jinfa, XU Shanyong. The feasibility analysis of breast conserving surgery after neoadjuvant chemotherapy in the treatment with advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 109-113.
[5]	BA Zhichang, WANG Xinxin, CUI Wanhui, GUO Fei, ZHANG Xiushi. Value of diffusion weighted magnetic resonance imaging in the monitoring of neoadjuvant chemotherapy efficacy for uterine cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(6): 518-522.
[6]	ZHU Hong,ZHU Li,HAN Shiyu,FANG Fang,YU Yang. The predictive value of DWI for progression free survival in patients with cervix cancer after neoadjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 519-523.
[7]	NING Siqing,ZHAN Botao,XU haisheng. The investigation of effects of TNP in the head and neck squamous cell carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 540-544.
[8]	SONG Yulin,WANG Jing. The screening and assessment of the neoadjuvant chemotherapy for the ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 553-556.
[9]	MA Rong,CHEN Xihai,GENG Xiaoxing,LIU Shuang,ZHANG Heng. The evaluation of effectiveness of concurrent chemoradiation for locally advanced cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 314-318.
[10]	TENG Chong,SONG Xiaowei,CAI Li. Effect and clinical significance of Ki-67 in neoadjuvant chemotherapy for breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(2): 188-192.
[11]	YIN Mingzhu,LOU Ge,CHEN Xiuwei,GU Taihua. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with concurrent chemoradiotherapy on locally advanced uterine cervix cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(1): 40-45.
[12]	WU Liangzhi, JIANG Nan, ZHANG Yi. Study on the molecule mechanisms efficacy of two kinds of neoadjuvant chemotherapy in locally and advanced cervix cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(5): 427-429.
[13]	XU Ye, GAO Ying, LOU Ge. A clinical observation on neoadjuvant chemotherapy for ovary tumor of advanced stage treated with paclitaxel liposome and nedaplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2008, 22(6): 512-513.

The comparison of clinical efficacy of SOX and XELOX in the neoadjuvant chemotherapy for advanced gastric carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 13

Recommended Articles

Metrics

Comments